PARIS - Thursday, June 7th 2012 [ME NewsWire]
(BUSINESS
WIRE)-- On June 28 and 29, academic thought leaders and high-ranking
officers from pharma, biotech and information technology companies will
gather in Paris at the 4th WIN Symposiumto present and discuss
breakthroughs that will bring personalized cancer medicine to the next
phase. The Symposium will address new ways to advance individualized
cancer therapy by applying new technologies, including targeted
therapeutics and diagnostic biomarkers, and by designing and conducting
innovative clinical trials in oncology. The program will include the
first-ever disclosure of new technologies that are able to predict the
efficacy of therapeutics for the treatment of cancer patients on an
individual basis.
Both sides - academia and industry -
will equally contribute to the presentations and discussions. Experts
participating from the academic side include: James Doroshow (NCI),
Ronald DePinho (USA), John Mendelsohn (USA); Alexander Eggermont
(France); William Dalton (USA), Richard L. Schilsky (USA), Leroy Hood
(Canada), and others. Industry will be represented by among others Brett
Davis (Oracle Corporation), Richard Gaynor (Eli Lilly and Company),
Steven Averbuch (Bristol-Myers Squibb), Nick Botwood (AstraZeneca),
Paolo Paoletti (GlaxoSmithKline), and Christopher Viehbacher (Sanofi).
The
program has received endorsements* by ASCO**, ESMO, UICC and INCa. It
has been recognized as one of educational value for medical specialists,
which is reflected by the awarding of 12 European CME credits and 17
ESMO MORA credits.
The 4th WIN Symposium is the next
annual of the WIN Consortium (www.winconsortium.org), a joint initiative
of Cancer Institute Gustave Roussy, France, and The University of Texas
- MD Anderson Cancer Center, USA, which brings together 22 cancer
centers from around the world and technology partners, including Agilent
Technologies, GE Healthcare, Life Technologies, and Foundation
Medicine.
Advance registration for the symposium at
reduced rates remains open until June 24 via the WIN Consortium website.
On-site registration in Paris will be open as of June 27.
(*)
These endorsements do not constitute medical advice. Health care
providers should exercise their own independent medical judgment.
(**)
This program has the American Society of Clinical Oncology’s approval
for quality of educational content. ASCO endorsement does not constitute
medical advice. Health care providers should exercise their own
independent medical judgment. ASCO® is a registered trademark of the
American Society of Clinical Oncology®. Used with permission. This is
not an ASCO sponsored event.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50302449&lang=en
Contacts
WIN Symposium
Congess by design
Dr. Vladimir Lazar, +31 (0)88 0898101
win@congressbydesign.com
No comments:
Post a Comment